Asep Medical secures $1M loan to fund working capital
What's the deal? Asep Medical HoldingsDealroom has a profile for this one. Try Dealroom → has entered a $1 million secured loan facility with an undisclosed arm's length private lender. The Vancouver-based investment issuer (CSE: ASEP) signed the agreement on October 8, 2026, with closing expected the following day.
The terms: The non-revolving term loan carries 12% annual interest and matures 24 months after execution. It is secured against all present and future personal property of the company, including accounts, equipment, inventory, cash, intellectual property, and proceeds.
What's the endgame? Proceeds will fund short-term working capital, ordinary operating expenses, and general corporate purposes. Asep can prepay the facility and accrued interest in whole or part before maturity.
What's behind the structure? No securities will be issued in connection with the facility, and no finder's fee, commission, or loan bonus is payable. The advance remains subject to conditions in the loan agreement and Canadian Securities Exchange acceptance, where required.
Asep invests in biotechnology research and development assets based on technologies developed over the past decade at the University of British ColumbiaDealroom has a profile for this one. Try Dealroom → under microbiologist Dr. Robert E. W. Hancock. It holds significant interests in two private companies: Sepset BiosciencesDealroom has a profile for this one. Try Dealroom →, which develops a sepsis diagnostic technology, and ABT InnovationsDealroom has a profile for this one. Try Dealroom →, which specialises in anti-biofilm technology.
The signal: For a small-cap biotech holding company, a non-dilutive debt facility covers near-term costs without issuing new shares — a step up that keeps the lights on while its patent portfolio matures.
Read more: hk.marketscreener.com
Image credit: Generated with Gemini
